(702) 683-8946

Monday - Friday 9am to 5pm



Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com




Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com




CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform




Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business




Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.


Latest News Releases From The Newsroom

Aehr Test Systems Receives Initial Production Order for Proprietary ABTS(TM) Burn-In and Test System Thermal Chambers

April 06th, 2017

Fremont, CA / CRWE PRESS RELEASE / April 6, 2017 - Aehr Test Systems (Nasdaq:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, announced today that it has received a production order of $850,000 for multiple Advanced Burn-in an. Read more

Neptune enters into Commercial Distribution Joint Venture in China with Shanghai Chonghe Marine Industry Co., Ltd.

April 06th, 2017

Laval, Québec, CANADA / CRWE PRESS RELEASE / April 5, 2017 - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ and TSX: NEPT) is pleased to announce that it has signed a commercial distribution joint venture agreement with Shanghai. Read more

Whitewave announces court order allowing for completion of merger with Danone

April 06th, 2017

Merger expected to be completed within five business days DENVER, Colo. / CRWE PRESS RELEASE / April 5, 2017 - The U.S. District Court for the District of Columbia (the "Court") has signed an order allowing The WhiteWave Foods Company (N. Read more

Barrick Announces Strategic Cooperation Agreement with Shandong Gold

April 06th, 2017

* As a first step, Shandong Gold will acquire 50 percent of the Veladero mine * As a second step, both companies will explore joint development of Pascua-Lama * As a third step, Shandong will evaluate further opportunities with Barrick All amoun. Read more

Tahoe Resources Declares Fourth Monthly Dividend For 2017

April 06th, 2017

VANCOUVER, British Columbia / CRWE PRESS RELEASE / April 6, 2017 - Tahoe Resources Inc. (“Tahoe” or the “Company”) (TSX: THO; NYSE: TAHO) is pleased to declare its fourth monthly dividend for 2017 of USD$0.02 per common s. Read more

Ballard Inks $11M Deal With Broad-Ocean For 200 Fuel Cell Engines in China Market

April 06th, 2017

VANCOUVER, CANADA and ZHONGSHAN, CHINA / CRWE PRESS RELEASE / April 5, 2017 - Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) today announced that it has entered into a definitive equipment supply agreement with Zhongshan Broad-Ocean Motor Co., . Read more

Uranium Resources Announces Positive Geophysical Results at its Columbus Basin Lithium Project

April 05th, 2017

CENTENNIAL, Colo. / CRWE PRESS RELEASE / April 5, 2017 - Uranium Resources, Inc. (URI) (Nasdaq: URRE; ASX: URI), an energy metals development company, announced today that its independent geophysical consultant has completed the review, integrat. Read more

Teck Reports Class A Share Conversion

April 05th, 2017

Vancouver, B.C. / CRWE PRESS RELEASE / April 5, 2017 - Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that Caisse de depot et placement (the “Caisse”) has tendered 1,576,166 Class A c. Read more

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (nera. Read more

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were . Read more